Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Profound Medical ( (TSE:PRN) ).
Profound Medical Corp. announced it will host a hybrid investor event during the American Urological Association’s Annual Meeting in Las Vegas on April 28, 2025. The event will feature presentations on the TULSA-PRO system, including its application in treating prostate diseases and the progress of the TULSA+ program, which integrates Siemens Healthineers’ MRI technology. This event highlights Profound’s commitment to advancing its medical technologies and enhancing its market position in the treatment of prostate diseases, potentially impacting stakeholders by showcasing the efficacy and versatility of its solutions.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company that specializes in developing and marketing customizable, incision-free therapies for the ablation of diseased tissue. The company is known for its TULSA-PRO technology, which combines real-time MRI, robotically-driven transurethral ultrasound, and closed-loop temperature feedback control to treat various prostate diseases. Profound also markets Sonalleve, a platform for treating uterine fibroids and palliative pain from bone metastases, and is exploring additional treatment markets.
YTD Price Performance: -15.14%
Average Trading Volume: 6,188
Technical Sentiment Signal: Buy
Current Market Cap: C$300.4M
See more data about PRN stock on TipRanks’ Stock Analysis page.